Vir Biotechnology, Inc. (NASDAQ:VIR) CEO Sells $474,286.40 in Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) CEO Backer Marianne De sold 79,712 shares of Vir Biotechnology stock in a transaction dated Thursday, April 3rd. The shares were sold at an average price of $5.95, for a total transaction of $474,286.40. Following the transaction, the chief executive officer now directly owns 769,505 shares of the company’s stock, valued at approximately $4,578,554.75. This trade represents a 9.39 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Vir Biotechnology Trading Down 6.4 %

Vir Biotechnology stock opened at $5.58 on Friday. The firm has a market cap of $765.26 million, a price-to-earnings ratio of -1.42 and a beta of 1.14. Vir Biotechnology, Inc. has a 12 month low of $5.49 and a 12 month high of $14.45. The stock has a fifty day simple moving average of $8.36 and a two-hundred day simple moving average of $8.29.

Vir Biotechnology (NASDAQ:VIR) last issued its earnings results on Wednesday, February 26th. The company reported ($0.76) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.09. The business had revenue of $12.37 million during the quarter, compared to analyst estimates of $8.14 million. Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. On average, equities research analysts forecast that Vir Biotechnology, Inc. will post -3.92 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. Point72 Asia Singapore Pte. Ltd. bought a new stake in Vir Biotechnology in the 4th quarter worth approximately $42,000. SBI Securities Co. Ltd. purchased a new position in shares of Vir Biotechnology in the 4th quarter worth $60,000. PNC Financial Services Group Inc. grew its holdings in shares of Vir Biotechnology by 31.8% in the fourth quarter. PNC Financial Services Group Inc. now owns 8,288 shares of the company’s stock worth $61,000 after acquiring an additional 1,999 shares during the period. KBC Group NV grew its holdings in shares of Vir Biotechnology by 136.5% in the fourth quarter. KBC Group NV now owns 8,970 shares of the company’s stock worth $66,000 after acquiring an additional 5,177 shares during the period. Finally, CIBC Asset Management Inc purchased a new stake in Vir Biotechnology during the fourth quarter valued at $74,000. 65.32% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

VIR has been the subject of several recent research reports. Morgan Stanley upgraded shares of Vir Biotechnology from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $10.00 to $20.00 in a report on Thursday, January 9th. Needham & Company LLC reiterated a “buy” rating and set a $19.00 price objective on shares of Vir Biotechnology in a research note on Thursday, February 27th. Leerink Partners increased their target price on Vir Biotechnology from $18.00 to $20.00 and gave the stock an “outperform” rating in a research note on Monday, January 13th. JPMorgan Chase & Co. raised their price target on Vir Biotechnology from $10.00 to $14.00 and gave the company a “neutral” rating in a report on Thursday, January 9th. Finally, Barclays upped their price target on shares of Vir Biotechnology from $26.00 to $31.00 and gave the stock an “overweight” rating in a research note on Friday, February 28th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, Vir Biotechnology has a consensus rating of “Moderate Buy” and an average target price of $35.67.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).